Announcements
- Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari – 30 juni 2023
- Infant Bacterial Therapeutics AB (publ) Interim report January 1 - June 30, 2023
- New number of shares and votes in IBT
- Nytt antal aktier och röster i IBT
- IBT announces outcome of its rights issue
- IBT offentliggör utfall i företrädesemissionen
- Ytterligare Infant Bacterial Therapeutics produkt beviljas “orphan drug” status av FDA
- Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation
- Futilitetsanalysen för IBTs Connection Study positiv
- The futility analysis for IBT’s Connection Study positive
More ▼
Key statistics
As of last trade Infant Bacterial Therapeutics AB (9IB:BER) traded at 8.04, -15.19% below its 52-week high of 9.48, set on Jan 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.60 |
---|---|
High | 8.06 |
Low | 7.56 |
Bid | 7.82 |
Offer | 8.28 |
Previous close | 7.60 |
Average volume | 0.00 |
---|---|
Shares outstanding | 13.02m |
Free float | 11.41m |
P/E (TTM) | -- |
Market cap | 1.16bn SEK |
EPS (TTM) | -9.90 SEK |
Data delayed at least 15 minutes, as of May 10 2024 16:00 BST.
More ▼